Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

T cells mediate anti-tumor immune responses and are the key target of immune checkpoint therapy, but they can also promote immune tolerance. A clear understanding of the specific contributions and biology of different T cell subsets is required to fully harness the curative potential of immunotherapies. Experts discuss the state of the field and key challenges for moving forward.

Original publication

DOI

10.1016/j.ccell.2021.11.010

Type

Journal article

Journal

Cancer Cell

Publication Date

13/12/2021

Volume

39

Pages

1549 - 1552

Keywords

Humans, Immunotherapy, Neoplasms, T-Lymphocytes